Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014

Cited by 1,771 works. doi:10.1016/s0140-6736(14)60958-2

Authors

References